Latest News

  • PARTNERSHIPS

    17 Mar 2026

    Why Novo Nordisk Is Putting $2 Billion Into a Pill

  • REGULATORY

    12 Mar 2026

    Medicare's GLP-1 Bridge: Who Gets In?

  • INNOVATION

    6 Mar 2026

    Altimmune's Liver Drug Moves Closer to the Finish Line

  • TECHNOLOGY

    4 Mar 2026

    AI Maps Brown Fat Genes for Next-Gen Weight Drugs

From Code to Clinic: AI Biotech Grows Up

Scientist pipetting samples in biotech laboratory

INSIGHTS

2 Mar 2026

AI drug developers face mounting pressure to turn machine learning breakthroughs into real clinical results

Automated laboratory system screening drug compounds in petri dish

INNOVATION

11 Feb 2026

The New Front Line in AI Drug Discovery

Deep EigenMatics tops 2025 AI drug patents, speeding early discovery in obesity and diabetes research

AstraZeneca logo displayed on glass office building facade

PARTNERSHIPS

10 Feb 2026

AstraZeneca Bets on AI to Rethink Obesity Care

AstraZeneca and CSPC join forces, blending AI and long-acting dosing to speed new obesity and diabetes drugs across global markets

Close-up of GLP-1 text under magnifying glass with obesity and diabetes terms

MARKET TRENDS

5 Feb 2026

Patients Take the Lead in US Metabolic Drug Pricing

Patients, not just policymakers or drugmakers, are reshaping access and pricing in the fast-growing US metabolic therapy market

AstraZeneca logo on pharmaceutical company headquarters

PARTNERSHIPS

3 Feb 2026

AstraZeneca Brings AI In-House to Speed Drug Discovery

AstraZeneca acquires Modella AI to embed data and AI directly into research, signaling how central artificial intelligence has become to m...

Clinician reviewing laboratory data beside test tubes in medical research setting

RESEARCH

30 Jan 2026

New Metabolic Data Reignite Interest in Liver-Targeted Lipid Drugs

Early clinical data revive a sidelined liver pathway, drawing fresh attention while leaving Phase 2 results as the real test

Illustration of a human liver showing cellular damage linked to metabolic disease

PARTNERSHIPS

20 Jan 2026

Roche’s 89bio Deal Heats Up the Race for MASH Drugs

Roche’s acquisition of 89bio signals rising confidence in late-stage MASH drugs and sharpens competition for metabolic liver disease treat...

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.